In order to prevent the grant of an interim measure / a preliminary injunction without prior hearing, the potential defendant may file a pre-emptive brief with the competent court; Art.
The FPC began to publish the dates of forthcoming public oral hearings on the website, at the bottom right of the entry page:
Further details of the scheduled oral hearing(s) can be found in the Case law Section, or via the hyperlink at the bottom right.
The following Guidelines were amended, effective as of 01 January 2013:
- Guidelines on Proceedings before the Federal Patent Court
- Guidelines on Independence
The prior versions can still be found here.
Case No. S2012_011 ¦ Decision of 21 November 2012 ¦ “Abweisung des Gesuchs um Erlass vorsorglicher Massnahmen wegen fehlender erfinderischer Tätigkeit”
First patent applications on the blockbuster drug Omeprazole date back to 1978; cf.
Case No. O2012_004 ¦ Decision of 24 August 2012 ¦ “Nichteintreten wegen ungenügendem Rechtsbegehren; Bemessung der Parteientschädigung”
This case started back in March 2010 at the cantonal court of Grisons.
Case No. D2012_019 ¦ Decision of 27 August 2012 ¦ “Schutzschrift; Benennung der Parteien”
This is the first published decision of the FPC pertaining to a pre-emptive brief.
Case No. O2012_037 ¦ Order of 30 July 2012 ¦ “Parteisprache Englisch, Verbindlichkeit der Wahl”
A major advantage of the Act on the FPC (PatCA) in an international environment is that the parties can agree to use English language; Art.
Case No. S2012_007 ¦ Decision of 23 August 2012 ¦ “Communication de la description”
This decision follows up on the prior decision of 14 June 2012, commented in a separate post.
Case No. O2012_022 ¦ Order of 31 July 2012 ¦ “Ablehnung Erläuterung”
This order of the FPC relates to a prior order of 03 May 2012, commented in a separate post.
Case No. O2012_025 ¦ Decision of 16 July 2012 ¦ “Gegenstandslosigkeit; Kosten- und Entschädigungsfolgen”
This case pertains to EP 1 175 904 B1 of Merck & Co., Inc., claiming the
[u]se of alendronate in the manufacture of a medicament for treating osteoporosis in a human in need of such treatment, where said medicament is orally administered to said human as a unit dosage comprising about 70 mg of the alendronate compound, on an alendronic acid active weight basis, according to a continuous schedule having a once-weekly dosing interval.
Case No. O2012_021 ¦ Order of 7 June 2012 ¦ “Zuständigkeit”
This case pertains to the performance-related heavy vehicle fee (HVF) levied in Switzerland.
Case No. S2012_005 ¦ Decision of 13 June 2012 ¦ “Zulässigkeit eines Feststellungsbegehrens, unlauterer Wettbewerb”
In 2005 the plaintiff entered into an R&D contract with a professor (now defendant).